IL149103A0 - 2,4-diaminopyrimidine compounds useful as immunosuppressants - Google Patents

2,4-diaminopyrimidine compounds useful as immunosuppressants

Info

Publication number
IL149103A0
IL149103A0 IL14910300A IL14910300A IL149103A0 IL 149103 A0 IL149103 A0 IL 149103A0 IL 14910300 A IL14910300 A IL 14910300A IL 14910300 A IL14910300 A IL 14910300A IL 149103 A0 IL149103 A0 IL 149103A0
Authority
IL
Israel
Prior art keywords
immunosuppressants
compounds useful
diaminopyrimidine compounds
diaminopyrimidine
useful
Prior art date
Application number
IL14910300A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL149103A0 publication Critical patent/IL149103A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14910300A 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds useful as immunosuppressants IL149103A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30
PCT/IB2000/001628 WO2001040215A1 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds usful as immunosuppressants

Publications (1)

Publication Number Publication Date
IL149103A0 true IL149103A0 (en) 2002-11-10

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14910300A IL149103A0 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds useful as immunosuppressants

Country Status (33)

Country Link
EP (1) EP1242403B1 (de)
JP (1) JP3955468B2 (de)
KR (1) KR20020059826A (de)
CN (1) CN1402720A (de)
AP (1) AP2002002530A0 (de)
AT (1) ATE315036T1 (de)
AU (1) AU1047601A (de)
BG (1) BG106695A (de)
BR (1) BR0015995A (de)
CA (1) CA2392971C (de)
CO (1) CO5261519A1 (de)
CZ (1) CZ20021703A3 (de)
DE (1) DE60025385T2 (de)
EA (1) EA200200411A1 (de)
EE (1) EE200200275A (de)
ES (1) ES2253266T3 (de)
GT (1) GT200000200A (de)
HN (1) HN2000000264A (de)
HU (1) HUP0203300A3 (de)
IL (1) IL149103A0 (de)
IS (1) IS6339A (de)
MA (1) MA26846A1 (de)
MX (1) MXPA02005350A (de)
NO (1) NO20022557L (de)
OA (1) OA12097A (de)
PA (1) PA8506801A1 (de)
PE (1) PE20010900A1 (de)
PL (1) PL355946A1 (de)
SV (1) SV2002000231A (de)
TN (1) TNSN00232A1 (de)
TR (1) TR200201431T2 (de)
UY (1) UY26455A1 (de)
WO (1) WO2001040215A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
HUP0302669A3 (en) * 2000-08-31 2004-03-29 Pfizer Prod Inc Pyrazole derivatives and pharmaceutical compositions containing them for treating diseases comprising abnormal cell growth and neurodegenerative diseases
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP1345922B1 (de) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als protein-kinase-inhibitoren
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP4733388B2 (ja) 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
KR20060133552A (ko) * 2004-01-16 2006-12-26 노파르티스 아게 2,4-디아미노피리미딘 및 심장근육발생 유도를 위한 그의용도
ATE512144T1 (de) * 2004-10-12 2011-06-15 Decode Genetics Ehf Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7622463B2 (en) 2006-02-14 2009-11-24 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
MX2008011661A (es) * 2006-03-16 2008-09-22 Novartis Ag Compuestos organicos heterociclicos para el tratamiento de melanoma en particular.
JP2010526825A (ja) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
WO2009051119A1 (ja) 2007-10-16 2009-04-23 Daiichi Sankyo Company, Limited ピリミジルインドリン化合物
AU2010299579A1 (en) 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
EP3055301B1 (de) * 2013-10-07 2019-11-20 Kadmon Corporation, LLC (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amin-derivate als rho kinase inhibitoren zur behandlung von autoimmun-erkrankungen
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000682A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (de) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
TR200201431T2 (tr) 2002-09-23
HUP0203300A2 (hu) 2003-02-28
EA200200411A1 (ru) 2002-10-31
CZ20021703A3 (cs) 2003-06-18
EP1242403A1 (de) 2002-09-25
AP2002002530A0 (en) 2002-06-30
AU1047601A (en) 2001-06-12
OA12097A (en) 2006-05-04
TNSN00232A1 (fr) 2005-11-10
UY26455A1 (es) 2001-07-31
MXPA02005350A (es) 2002-12-11
DE60025385D1 (de) 2006-03-30
CO5261519A1 (es) 2003-03-31
KR20020059826A (ko) 2002-07-13
PE20010900A1 (es) 2001-09-08
GT200000200A (es) 2002-05-23
CN1402720A (zh) 2003-03-12
ES2253266T3 (es) 2006-06-01
MA26846A1 (fr) 2004-12-20
PA8506801A1 (es) 2002-04-25
JP2003515602A (ja) 2003-05-07
NO20022557D0 (no) 2002-05-29
EE200200275A (et) 2003-10-15
BG106695A (bg) 2002-12-29
HN2000000264A (es) 2001-05-21
IS6339A (is) 2002-04-12
DE60025385T2 (de) 2006-08-24
CA2392971C (en) 2008-10-07
HUP0203300A3 (en) 2003-10-28
JP3955468B2 (ja) 2007-08-08
WO2001040215A1 (en) 2001-06-07
PL355946A1 (en) 2004-05-31
BR0015995A (pt) 2002-08-06
EP1242403B1 (de) 2006-01-04
CA2392971A1 (en) 2001-06-07
NO20022557L (no) 2002-05-29
ATE315036T1 (de) 2006-02-15
SV2002000231A (es) 2002-07-16

Similar Documents

Publication Publication Date Title
AP2002002529A0 (en) 2,4-Diaminopyrimidine compounds useful as immunosupressants
IL149103A0 (en) 2,4-diaminopyrimidine compounds useful as immunosuppressants
HK1044757A1 (en) Pyrimidinone compounds.
IL146100A0 (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
HK1043127A1 (en) Compounds useful as anti-inflammatory agents.
SI2308855T1 (sl) 2,4-diaminopirimidinski derivati
HK1061852A1 (en) 4,5-dihydro-ih-pyrazole derivatives having cb1-antagonistic activity
ZA200108000B (en) Cosmetic compounds.
MXPA02001088A (es) 2-pirazolin-5-onas..
AU4787301A (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
ZA200108968B (en) New compounds.
ZA200110413B (en) Crystalline 1-methylcarbapenem compounds.
HK1032815A1 (en) Condenser
EG23909A (en) Vatamin d, analogs
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
MXPA01011760A (es) Compuestos novedosos de difeniletileno.
IL149424A0 (en) 14,15-beta-methylene substituted androgens
GB2355714B (en) Ammonium 3,5-diaminopicrate
MXPA02000261A (es) Aminoindanos novedosos.
GC0000195A (en) Benzoamido- and thiophenecarboxyamido-1,2,3,4-tetrahydroisoquinol-7-ine compunds as anticonvulsant agents
GB2371543B (en) 3,3,5,5-Tetraalkyl-piperazin-2,6-dione stabilizers
IL146124A0 (en) 1,5-benzodiazepine derivatives
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
ZA200201714B (en) Novel compound F-15078.
IL165436A0 (en) 7,10-bis-trichlotoacetyl-10 deactylbaccatin III